Racura Oncology

Racura Oncology seeks collaborations to advance research on bisantrene’s mechanism of action or its use in oncology.

Racura Oncology has collaborated with leading scientific and medical institutions globally, including Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle.

In a webinar, Racura Oncology CEO Dr. Daniel Tillett discusses the company’s drug development journey and bisantrene’s potential growth opportunities.

The page identifies Racura Oncology as one of the most promising oncology therapeutics companies.

Racura Oncology CEO Dr. Daniel Tillett discusses the company’s drug development process, including bisantrene’s potential for cancer treatment and cardioprotection, and answers investor questions.

Racura Oncology is reformulating bisantrene to prevent heart damage in chemotherapy, with a phase 1 trial planned for early 2025. The company reports promising results from a phase 1b/2 trial using bisantrene in acute myeloid leukemia.

Career Opportunities Racura is growing and welcomes suitably qualified and experienced applicants to submit their resumes when career opportunities become available. Please refer to any current opportunities below.

The video introduces Racura Oncology’s Chief Medical Officer Dr. Jose Iglesias, who discusses his oncology career and expertise.

Silencing Cancer

Corporate Governance Plan Corporate Governance Statement Board of Directors’ Skills Matrix Replacement Constitution

Racura Oncology at the heart of cancer care